Update on sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patient

被引:0
|
作者
Franceschini, Gianluca [1 ]
Di Leone, Alba [1 ]
Sanchez, Alejandro Martin [1 ]
D'Archi, Sabatino [1 ]
Terribile, Daniela [1 ]
Magno, Stefano [1 ]
Scardina, Lorenzo [1 ]
Masetti, Riccardo [1 ]
机构
[1] Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli, Dept Woman Child & Publ Hlth, IRCCS,Div Breast Surg, Largo Agostino Gemelli 8, I-00168 Rome, Italy
关键词
Axillary treatment; Breast cancer; Neoadjuvant chemotherapy; Sentinel lymph node biopsy; AXILLARY DISSECTION; MANAGEMENT;
D O I
暂无
中图分类号
R61 [外科手术学];
学科分类号
摘要
Today, sentinel lymph node biopsy (SLNB) is considered the gold standard for axillary staging in early breast cancer patients with clinically negative lymph nodes (cNO). SLNB allows to determine the axillary lymph node status sparing the axillary dissection (AD) and its potential complications (seroma formation, loss of sensation, shoulder dysfunction and lymphedema) On the other hand, SLNB for nodal staging in breast cancer patients with clinically negative lymph nodes after neoadjuvant chemotherapy (ycN0) is a highly debated topic due to different reported success rates. In order to optimize oncological results, high identification rate (> 90%) and false negative rate as low as possible (< 10%) should always be obtained when performing SLNB after neoadjuvant chemotherapy. The success rates of SLNB after neoadjuvant chemotherapy (NAC) mainly depend on the clinical lymph node status pre-NAC. In patients with pre-NAC clinically negative nodes (cN0) and at restaging with post-NAC clinically negative nodes (ycN0), SLNB after chemotherapy should be performed because it is an accurate and safe procedure. In patients with pre-NAC clinically positive nodes (cN+) and at restaging with post-NAC clinically negative nodes (ycN0), SLNB after chemotherapy might be considered thanks to the high lymph nodal pathologic complete response rate; however, in this last setting, individual ability, technical skills and repetitive performance of specific tasks must always be followed to improve the identification rate and false negative rate. AD may be avoided only if sentinel lymph node is negative [ypN0(sn)J; instead, to date, patients with metastatic sentinel lymph node after neoadjuvant chemotherapy, even with only isolated tumor cells, fypN+(sn) including ypN0i+(sn) and ypN1mic(sn)J should always be treated with AD. However, NAC significantly increases the difficulties and complexity of axillary surgical management. A personalized multidisciplinary path in specialized breast centers should ensure an accurate clinical counselling and refined patient selection for SLNB post-NAC.
引用
收藏
页码:465 / 468
页数:4
相关论文
共 50 条
  • [21] Is sentinel lymph node biopsy after neoadjuvant chemotherapy feasible in Chinese patients with invasive breast cancers?
    Cheung, Tanfo T.
    Suen, Dacita T. K.
    Kwong, Ava
    ANZ JOURNAL OF SURGERY, 2009, 79 (10) : 719 - 723
  • [22] Sentinel lymph node biopsy in breast cancer after neoadjuvant chemotherapy. A pilot study
    Piato, JRM
    Barros, ACSD
    Pincerato, KM
    Sampaio, APQ
    Pinotti, JA
    EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2003, 29 (02): : 118 - 120
  • [23] Sentinel lymph node biopsy after neoadjuvant systemic chemotherapy in patients with breast cancer: a prospective pilot trial
    Medina-Franco, Heriberto
    Salgado-Nesme, Noel
    Zeron-Medina-Cuairan, Jorge
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2008, 60 (05): : 390 - 394
  • [24] Sentinel lymph node biopsy in patients with clinically negative lymph node after neoadjuvant chemotherapy
    Park, Sung-Jin
    Lee, Woo-Yong
    Yang, Geun-Ho
    Park, Kyeongmee
    Han, Sehwan
    JOURNAL OF BREAST CANCER, 2007, 10 (04) : 254 - 257
  • [25] Internal Mammary Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer
    Bi, Zhao
    Chen, Peng
    Liu, Jingjing
    Liu, Yanbing
    Qiu, Pengfei
    Yang, Qifeng
    Zheng, Weizhen
    Wang, Yongsheng
    JOURNAL OF BREAST CANCER, 2018, 21 (04) : 442 - 446
  • [26] Reliability of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients
    Han, Ahram H
    Moon, Hyeong-Gon
    Kim, Jisun
    Ahn, Soo Kyung
    Park, In Ae
    Han, Wonshik
    Noh, Dong-Young
    JOURNAL OF BREAST CANCER, 2013, 16 (04) : 378 - 385
  • [27] Sentinel Lymph Node Biopsy in Locally Advanced Breast Cancer After Neoadjuvant Chemotherapy-an Indian Perspective
    Arjunan, Ravi
    Ramamani, Tiwari Ajeet
    Ramachandra, Chowdappa
    Swamyvelu, Krishnamurthy
    Chunduri, Srinivas
    Althaf, Syed
    Usha, Amirtham
    Namrata, Ranganath
    INDIAN JOURNAL OF SURGICAL ONCOLOGY, 2020, 11 (02) : 242 - 247
  • [28] The use of blue dye alone for sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initially node-positive breast cancer
    Cavalcante, Francisco Pimentel
    Zerwes, Felipe Pereira
    Souza, Alessandra Borba Anton
    Ziegelmann, Patricia Klarmann
    Alcantara, Ryane
    Cardoso, Amanda
    Mattar, Andre
    Millen, Eduardo Camargo
    Frasson, Antonio Luiz
    EJSO, 2024, 50 (03):
  • [29] Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: A systematic review
    van Deurzen, Carolien H. M.
    Vriens, Birgit E. P. J.
    Tjan-Heijnen, Vivianne C. G.
    van der Wall, Elsken
    Albregts, Mirjam
    van Hilligersbery, Richard
    Monninkhof, Evelyn M.
    van Diest, Paul J.
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (18) : 3124 - 3130
  • [30] Sentinel lymph node biopsy with carbon nanoparticle suspension after neoadjuvant chemotherapy for breast cancer patients
    Wei, N.
    Hou, J.
    Chen, J.
    Dai, M.
    Du, K.
    Wang, S.
    Ni, Q.
    ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND, 2021, 103 (10) : 752 - 756